Related Experiment Videos
Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure
K Witte1, S Thackray, T Banerjee
1The University of Hull, Department of Cardiology, Academic Unit of Cardiology, Castle Hill Hospital, Kingston upon Hull, UK.
Insights
Three major clinical trials—ELITE-II, BEST, and CHAMP—offer insights into managing heart failure and myocardial infarction. While not mandating practice changes, they provide valuable data, with the IMPRESS trial showing promise for omapatrilat in heart failure treatment.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Heart failure and myocardial infarction management are critical areas in cardiovascular medicine.
- Existing clinical practices guide current treatment strategies.
- New therapeutic agents are continuously evaluated for improved patient outcomes.
Purpose of the Study:
- To present findings from the ELITE-II, BEST, and CHAMP trials.
- To assess the impact of these trials on current clinical practice for heart failure and myocardial infarction.
- To evaluate the potential of omapatrilat, a vasopeptidase inhibitor, as a novel treatment for heart failure.
Main Methods:
- Reporting of results from the ELITE-II, BEST, and CHAMP clinical trials.
- Analysis of data to inform clinical practice guidelines.
- Evaluation of the IMPRESS trial investigating omapatrilat.
Main Results:
- The ELITE-II, BEST, and CHAMP trials provide new information for managing heart failure and myocardial infarction.
- None of the reported trials necessitate a significant alteration in current clinical practice.
- The IMPRESS trial demonstrated omapatrilat as a promising treatment option for heart failure.
Conclusions:
- Clinical trial data from ELITE-II, BEST, and CHAMP offer valuable insights but do not mandate immediate changes in practice.
- The vasopeptidase inhibitor omapatrilat shows potential as a new therapeutic agent for heart failure management, as suggested by the IMPRESS trial.
Abstract:
The ELITE-II, BEST and CHAMP Trials were reported for the first time at the American Heart Association in November 1999. These trials provide valuable new information to guide clinical practice in the management of heart failure and of myocardial infarction, although none mandate a major change from current clinical practice. The IMPRESS trial of the vasopeptidase inhibitor, omapatrilat, indicated a promising new treatment for the management of heart failure.